HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations
- PMID: 29561264
- PMCID: PMC5896952
- DOI: 10.7554/eLife.34271
HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations
Abstract
HIV-1 entry into cells requires binding of the viral envelope glycoprotein (Env) to receptor CD4 and coreceptor. Imaging of individual Env molecules on native virions shows Env trimers to be dynamic, spontaneously transitioning between three distinct well-populated conformational states: a pre-triggered Env (State 1), a default intermediate (State 2) and a three-CD4-bound conformation (State 3), which can be stabilized by binding of CD4 and coreceptor-surrogate antibody 17b. Here, using single-molecule Fluorescence Resonance Energy Transfer (smFRET), we show the default intermediate configuration to be asymmetric, with individual protomers adopting distinct conformations. During entry, this asymmetric intermediate forms when a single CD4 molecule engages the trimer. The trimer can then transition to State 3 by binding additional CD4 molecules and coreceptor.
Keywords: HIV-1 Envelope; Single molecule FRET; infectious disease; microbiology; molecular biophysics; structural biology; virus; virus entry.
Conflict of interest statement
XM, ML, JG, DT, XH, ZZ, HZ, RA, JA, SB, PK, JM No competing interests declared, WM Patent applications pertaining to this work are U.S. Patent Application 13/202,351, Methods and Compositions for Altering Photophysical Properties of Fluorophores via Proximal Quenching (S.C.B., Z.Z.); U.S. Patent Application 14/373,402 Dye Compositions, Methods of Preparation, Conjugates Thereof, and Methods of Use (S.C.B., Z.Z.); and International and US Patent Application PCT/US13/42249 Reagents and Methods for Identifying Anti-HIV Compounds (S.C.B., J.B.M., W.M.). S.C.B. is a co-founder of Lumidyne Corporation
Figures
References
-
- Arthos J, Cicala C, Steenbeke TD, Chun TW, Dela Cruz C, Hanback DB, Khazanie P, Nam D, Schuck P, Selig SM, Van Ryk D, Chaikin MA, Fauci AS. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. The Journal of Biological Chemistry. 2002;277:11456–11464. doi: 10.1074/jbc.M111191200. - DOI - PubMed
-
- Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491. doi: 10.1038/nature14411. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI005023-17/NH/NIH HHS/United States
- R01 GM098859/GM/NIGMS NIH HHS/United States
- GM098859/NH/NIH HHS/United States
- R01 GM116654/GM/NIGMS NIH HHS/United States
- P01 GM056550/GM/NIGMS NIH HHS/United States
- AI116262/NH/NIH HHS/United States
- GM103310/NH/NIH HHS/United States
- GM116654/NH/NIH HHS/United States
- P30 AI042853/AI/NIAID NIH HHS/United States
- K22 AI116262/AI/NIAID NIH HHS/United States
- Z01 AI005023/ImNIH/Intramural NIH HHS/United States
- P41 GM103310/GM/NIGMS NIH HHS/United States
- AI042853/NH/NIH HHS/United States
- GM056550/NH/NIH HHS/United States
- Irvington Fellows Program/CRI/Cancer Research Institute/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
